- Published on
Ophthalmology – Acute Anterior Uveitis
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
0 Comments
